Hidden-driver inference reveals synergistic brain-penetrant therapies for medulloblastoma
Liu, J.; Yang, X.; Zhu, M.; Dong, X.; Zhou, H.; Bianski, B.; Jonchere, B.; Lin, W.; Fu, X.; Bhatara, S.; Yang, J.; Lim, S.-E.; Yang, L.; Freeman, B. B.; Wang, A. S.; Jiang, R.; Chen, T.; Robinson, G. W.; Roussel, M. F.; Merchant, T. E.; Gajjar, A.; Yu, J.
Show abstract
Effective therapies for high-risk medulloblastoma (MB), particularly MYC-driven Group 3 (G3) MB, remain elusive due to limited druggable mutations, poor blood-brain barrier (BBB) penetration, and rapid resistance. We developed SINBA (Synergy Inference by Data-driven Network-Based Bayesian Analysis), a systems biology framework that computationally prioritizes synergistic, BBB-permeable drug combinations by identifying hidden drivers sustaining oncogenic programs. Integrating MB-specific networks, transcriptomic data, and drug-gene interactions, SINBA nominated 32 candidates, of which 19 were experimentally validated as synergistic. Through iterative prioritization and experimental refinement, the MEK inhibitor mirdametinib and p38 inhibitor regorafenib emerged as the top brain-penetrant pair, suppressing G3 MB progression and extending survival in xenograft and immunocompetent models, with efficacy enhanced by low-dose radiation. Single-cell analysis revealed selective targeting of developmental origins and immune reprogramming. These findings establish SINBA as a computationally assisted discovery framework for clinically actionable combinations in high-risk MB.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations 95%
- Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones 94%
- Community assessment of cancer drug combination screens identifies strategies for synergy prediction 94%
Similar papers in this journal
- Multiplexed mosaic tumor models reveal natural phenotypic variations in drug response within and between populations 95%
- Additivity predicts the efficacy of most approved combination therapies for advanced cancer 94%
- Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance 93%
Similar papers in this journal
- AI-Driven Predictive Biomarker Discovery with Contrastive Learning to Improve Clinical Trial Outcomes 94%
- Targeting the mSWI/SNF Complex in POU2F-POU2AF Transcription Factor-Driven Malignancies 94%
- Systematic Elucidation and Pharmacological Targeting of Tumor-Infiltrating Regulatory T Cell Master Regulators 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.